NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Price, News & Analysis

Virios Therapeutics logo
$1.06 -0.05 (-4.50%)
As of 11/16/2026

About Virios Therapeutics Stock (NASDAQ:VIRI)

Advanced

Key Stats

Today's Range
$1.02
▼
$1.18
50-Day Range
$1.03
▼
$2.04
52-Week Range
$0.13
▼
$1.04
Volume
69,906 shs
Average Volume
1.05 million shs
Market Capitalization
$20.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Virios Therapeutics is a clinical-stage biotechnology company that has focused on developing antiviral-based treatments for conditions it believes may be associated with viral activation. Its research has centered on fibromyalgia and other chronic illnesses.

The company’s lead program, IMC-1, combines famciclovir, an antiviral medicine, with celecoxib, an anti-inflammatory drug. Virios developed the combination to investigate whether suppressing herpesvirus activity could help address fibromyalgia symptoms. The company has also explored IMC-2 for other chronic conditions.

Virios is based in Alpharetta, Georgia, and its work has been focused on drug development rather than marketing approved products. Its programs have been investigational and subject to clinical evaluation.

AI Generated. May Contain Errors.

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIRI Stock News Headlines

Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
See More Headlines

VIRI Stock Analysis - Frequently Asked Questions

Virios Therapeutics' stock was trading at $4.16 at the beginning of 2026. Since then, VIRI stock has decreased by 74.5% and is now trading at $1.06.

Virios Therapeutics, Inc. (NASDAQ:VIRI) issued its earnings results on Thursday, August, 8th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02.

Virios Therapeutics (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Atossa Genetics (ATOS), Beyond Meat (BYND), Palantir Technologies (PLTR), SNDL (SNDL), Tiziana Life Sciences (TLSA), AMC Entertainment (AMC) and Ford Motor (F).

Company Calendar

Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VIRI
CIK
1818844
Fax
N/A
Employees
5
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($0.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-130.33%
Return on Assets
-115.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.27
Quick Ratio
7.27

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
5.30

Miscellaneous

Outstanding Shares
19,258,000
Free Float
16,909,000
Market Cap
$20.41 million
Optionable
No Data
Beta
1.58

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:VIRI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners